FLOSEAL Hemostatic Matrix is intended to control bleeding during cardiac and spinal surgeries, indicated for use as an adjunct to “hemostasis when control of bleeding by ligature or conventional procedure is ineffective or impractical.”
Journal of Medical Economics published the studies.
Spinal surgery analysis
1. Researches discovered potential hospital cost savings of $151 per major and $574 per severe spinal surgery when using FLOSEAL, compared to using Somerville, N.J.-based Ethicon’s SURGIFLO.
2. Hospitals would reap these savings with FLOSEAL due to shorter operative room time, a lower blood transfusion rate and lower product volume use.
Cardiac surgery analysis
3. Researchers compared potential cost savings when using FLOSEAL versus SURGIFLO, and found savings of $1.5 million annually for an average U.S. hospital.
4. The savings would result from fewer major and minor complications, surgical revisions, blood product transfusions and operating time hours.
More articles on devices:
Mizuho OSI opens 4th global training center — 5 details
Medacta reaffirms partnership with OREF — 5 observations
Medacta offers 4-step program for surgeons to successfully perform outpatient hip, knee & spine surgery
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
